{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/Test_New_Phase_Variations","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00343941","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized","arm_groups":[],"assignment":"Parallel Assignment","brief_summary":"This is a pilot study designed to determine a dose and schedule of Tucaresol that can be administered to HIV-1 infected subjects on HAART (highly active antiretroviral therapy) with viral suppression without occurrence of significant adverse events and that results in significant changes in cell mediated immunity.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV Infection","LookupValue_OneLinkTx":""}],"created_date":"06/05/2021 09:25:17","criteria":"Inclusion Criteria: - Currently on licensed triple combination therapy, which is defined as two nucleoside analogues (2 NRTI) (excluding Abacavir) and a protease inhibitor (PI) (including boosted PI regimens) or non nucleoside reverse transcriptase inhibitor (NNRTI). - Must be on the same treatment for at least 3 months prior to study without plans to alter therapy for the next 3 months. Plasma HIV-1 RNA (ribonucleic acid)< 50 copies/mL at screening with a documented history of continuous suppression defined as: the last two readings < 50 copies/mL for a period of at least 3 months prior to screening. - Documented CD4+ lymphocyte cell count =350 cells/ml at screening with at least one reading =350 cells/mL in the preceding 3 months and CD4 nadir >200 cells/ml. HBsAg (human hepatitis B Virus surface antigen) and HCV-Ab (human hepatitis C Virus antibody) negative. Exclusion Criteria: - History of hyperimmune or allergic reactions to drug treatment within 3 months prior to study.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"45","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"no","id":"54f15fbd-4bdb-52f5-82cd-de81136a9b0b","internal":{"content":null,"contentDigest":"f95a22c7d6cc4daf847ecc2099b6998f","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Currently on licensed triple combination therapy, which is defined as two nucleoside analogues (2 NRTI) (excluding Abacavir) and a protease inhibitor (PI) (including boosted PI regimens) or non nucleoside reverse transcriptase inhibitor (NNRTI). - Must be on the same treatment for at least 3 months prior to study without plans to alter therapy for the next 3 months. Plasma HIV-1 RNA (ribonucleic acid)< 50 copies/mL at screening with a documented history of continuous suppression defined as: the last two readings < 50 copies/mL for a period of at least 3 months prior to screening. - Documented CD4+ lymphocyte cell count =350 cells/ml at screening with at least one reading =350 cells/mL in the preceding 3 months and CD4 nadir >200 cells/ml. HBsAg (human hepatitis B Virus surface antigen) and HCV-Ab (human hepatitis C Virus antibody) negative. Exclusion Criteria: - History of hyperimmune or allergic reactions to drug treatment within 3 months prior to study.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"Tucaresol tablets 25 mg","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":null,"is_high_value":false,"is_ind_study":false,"keywords":["HIV-1 infection","Tucaresol","Viral suppression"],"last_follow_up_date":"08/12/2005 00:00:00","links":[],"locations":[{"City":"Busto Arsizio (VA)","Latitude":"45.611892","CountryDisplay":"Italy","Longitude":"8.8531265","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"21052","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Firenze","Latitude":"43.8087582","CountryDisplay":"Italy","Longitude":"11.2693842","Name":"GSK Investigational Site","StateDisplay":"Toscana","PostalCode":"50139","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bergamo","Latitude":"45.6935813","CountryDisplay":"Italy","Longitude":"9.65008","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"24128","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Milano","Latitude":"45.5145841","CountryDisplay":"Italy","Longitude":"9.1358629","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20157","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Milano","Latitude":"45.5000627","CountryDisplay":"Italy","Longitude":"9.2273552","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20127","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bagno a Ripoli (FI)","Latitude":"43.7592388","CountryDisplay":"Italy","Longitude":"11.2920619","Name":"GSK Investigational Site","StateDisplay":"Toscana","PostalCode":"50126","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Padova","Latitude":"45.397898","CountryDisplay":"Italy","Longitude":"11.9046617","Name":"GSK Investigational Site","StateDisplay":"Veneto","PostalCode":"35128","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bagno a Ripoli (FI)","Latitude":"43.7592388","CountryDisplay":"Italy","Longitude":"11.2920619","Name":"GSK Investigational Site","StateDisplay":"Toscana","PostalCode":"50126","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bergamo","Latitude":"45.6935813","CountryDisplay":"Italy","Longitude":"9.65008","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"24128","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Busto Arsizio (VA)","Latitude":"45.611892","CountryDisplay":"Italy","Longitude":"8.8531265","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"21052","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Firenze","Latitude":"43.8087582","CountryDisplay":"Italy","Longitude":"11.2693842","Name":"GSK Investigational Site","StateDisplay":"Toscana","PostalCode":"50139","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Milano","Latitude":"45.5000627","CountryDisplay":"Italy","Longitude":"9.2273552","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20127","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Milano","Latitude":"45.5145841","CountryDisplay":"Italy","Longitude":"9.1358629","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20157","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Padova","Latitude":"45.397898","CountryDisplay":"Italy","Longitude":"11.9046617","Name":"GSK Investigational Site","StateDisplay":"Veneto","PostalCode":"35128","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"}],"masking":"Double Blind","maximum_age_raw":"64 Years","maximum_age":"64","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"06/07/2021 18:59:26","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A phase II multicentre, randomized, double blind, parallel group, placebo controlled pilot study of tucaresol at two dosing levels (25,50 mg) in HIV-1 infected adult subjects with plasma HIV-1 RNA < 50 copies/ml on stable highly active antiretroviral therapy regimen for at least 3 months","org_study_id":"Test_New_Phase_Variations","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"PHASE I","primary_compl_date":null,"primary_outcomes":[{"outcome_description":"","outcome_measure":"Significant increase from baseline in IFN-g (Interferon gamma) EliSpot cellular responses at day 70 following peptide stimulation of PBMC (peripheral blood monocytic cells) of subjects after the second dosing cycle of study drug (days 56 to 62).","outcome_time_frame":"","outcome_safety_issue":null}],"product_name":"tucaresol","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Proportion of subjects developing drug related and treatment-limiting Adverse Events leading to discontinuation of study drug during the period of study and follow-up.","outcome_time_frame":"","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"11/24/2004 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"Test_New_Phase_Variations"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}